Abstract Library

#4534 Development of new 3D in vitro models for pancreatic neuroendocrine tumours (PanNETs)

Introduction: Current PanNET in vitro models struggle to accurately replicate the tumour’s biology and microenvironment, limiting understanding of the mechanisms underlying PanNET behaviour and drugs response.

Conference:

Presenting Author:

Authors: Battistella A, Pinos R, Barbaglio F, Capurso G, Schiavo Lena M,

Keywords: Preclinical models, Pan NET, microenvironment, bioprinting, tumour slices, drug testing,

#4312 Developing innovative, genetically modified, proliferation-regulated patient-derived models representing human well-differentiated GEP-NETs for drug screening

Introduction: The slow-growing nature of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) has limited the development of clinically relevant models, hindering the discovery in the field.

Conference:

Presenting Author: Zuo X

Authors: Zuo X, Liu Y, Maxwell J, Halperin D, Dasari A,

Keywords: Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumour, Patient-Derived Cancer Model, Doxycycline-Controlled Genetic Modification, Drug Screening,

#3326 Drug sensitivity profiles of PNET, SBNET and NEC spheroids

Introduction: Neuroendocrine neoplasms (NENs) are rare cancers that arise from neuroendocrine cells. NENs are classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Few mutations have been identified for NETs from the small bowel (SBNETs) and pancreas (PNETs). SBNETs and PNETs are generally slow growing but they commonly metastasize to the liver and can become aggressive cancers. NECs often harbour mutations in key cell cycle genes (TP53 and RB) and are highly proliferative. Little is known about the drug sensitivity profile of SBNET, PNET and NECs due to the lack of cellular and animal models of these malignancies. Recently, we have developed a protocol to culture NET and NEC cells from patient tumors as patient-derived spheroids and showed that they express NEN markers.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ear P

Authors: Ear P, Tran C, Li G, Abusada E, Mudd J,

Keywords: PNET, SBNET, NEC, drug testing, spheroids,

#2898 Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening

Introduction: The incidence of neuroendocrine tumors (NETs) from the small bowel (SBNETs) has increased markedly over the past several decades. Many patients with these tumors present with metastatic disease, and research into new treatment options for these tumors have been hindered by the limited number of patient-derived SBNET cell lines and in vivo models available for drug testing.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ear P

Authors: Ear P, Tran C, Li G, Kaemmer C, Ellen A,

Keywords: SBNET, drug screening, spheroids, PDX models, precision medicine,